Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Devimistat plus high-dose cytarabine and mitoxantrone versus HAM in older patients with relapsed or refractory acute myeloid leukemia
2018-001588-22Phase 3Completed
- Sponsor
- Cornerstone Pharmaceuticals
- Start
- Jan 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of devimistat in acute myeloid leukemia (AML) (2 arms), sponsored by Cornerstone Pharmaceuticals. Primary endpoint: Complete remission. Started Jan 2019; status: completed.
02
Drugs
devimistat
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on 2018-001588-22.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2018-001588-22.